Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Autolus

30.07.2020

Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, August 6, 2020.
OMass therapeutics

28.07.2020

OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director

OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies to drive drug discovery in high definition, today announced the appointment of Dr Nathalie Franchimont as a Non-Executive Director. Nathalie brings more than 15 years of leadership experience in biotechnology and pharma industries.
Freeline

20.07.2020

Freeline files registration statement for proposed initial public offering in the United States

Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.
Freeline

13.07.2020

Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Freeline, a clinical stage, Adeno-Associated Virus (AAV) based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced new data on its AAV gene therapy product candidate, FLT180a, in severe Haemophilia B patients at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress. The data presented in an oral presentation by Professor Pratima Chowdary of the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital UK and UCL Cancer Institute, and Principal Investigator for the study, demonstrated with data up to two years for the earliest cohort, that a dose of between 7.5e11 and 9.75e11 vg/kg has the potential to create durable Factor IX (FIX) activity levels in the normal range in patients with severe Haemophilia B.
Achilles Therapeutics

07.07.2020

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that it has appointed Daniel Hood as Chief Legal Officer. Dan is a highly experienced lawyer with more than 13 years’ experience working in-house within the pharmaceutical and life sciences sector which follows 10 years in private practice.
Freeline

30.06.2020

Freeline Closes $120 Million Series C Financing Round

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million extended Series C financing. The financing augments Syncona’s previously announced Series C investment in Freeline of $40 million (£30.6 million) with an additional $80 million (£61.2 million) of new capital. The round was led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.
Freeline

30.06.2020

Freeline Announces Additional Financing Plans

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States. The timing and the terms of any such additional capital raising have not yet been determined and are subject to market conditions and other factors. There is no assurance that any such additional capital raising will be completed.
Freeline

29.06.2020

Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that Professor Pratima Chowdary of the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital UK and UCL Cancer Institute, and Chief investigator for the study, will present data in a late-breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on behalf of co-authors, which will be held virtually 12-14 July 2020. In addition, Freeline has five posters at the conference and will be presenting data on the Factor IX Padua variant and health economics from its Adeno-Associated Virus (AAV)-based haemophilia gene therapy platform.
Achilles Therapeutics

23.06.2020

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC). In May 2020, Achilles dosed the first patient with cNeT in its Phase I/II THETIS study in recurrent or metastatic malignant melanoma.
Autolus

22.06.2020

Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting

Conference Call and Webcast to be held Thursday, June 25, 2020 at 8:30 AM EDT / 1:30 PM BST Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced preclinical data related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22 - 24, 2020.

Load More